Navigation Links
NxStage Announces Presentation of Data at the American Society of Nephrology's Renal Week 2008 Annual Meeting
Date:8/22/2008

LAWRENCE, Mass., Aug. 22 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that the interim quality of life analysis from the FREEDOM study will be presented during the American Society of Nephrology Renal Week 2008 Annual Meeting taking place November 4-9, 2008, in Philadelphia, Pennsylvania. An abstract entitled "Daily Home HD (DHD) Improves Quality of Life (QoL) Measures, Depressive Symptoms and Recovery Time: Interim Results from the FREEDOM Study," is scheduled to be presented on Friday, November 7, 2008 at 4:00 p.m.

Sponsored by NxStage, and implemented in collaboration with up to 70 U.S. dialysis clinics and the United States Renal Data System (USRDS), FREEDOM (Following Rehabilitation, Economics, and Everyday Dialysis Outcome Measurements) is a prospective study to quantify the clinical benefits and cost savings of daily therapy administered to Medicare patients with the NxStage System One versus conventional thrice-weekly dialysis.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, any unanticipated delay in presenting the QoL data relating to the FREEDOM study and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Kristen K. Sheppard, Esq.

VP, Investor Relations

ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NxStage Reports Second Quarter 2008 Financial Results
2. NxStage Announces $43 Million Private Placement of Equity Securities
3. NxStage Medical Reports First Quarter 2008 Results
4. NxStage Announces Supply Agreement With Kawasumi Laboratories for Blood Tubing Sets
5. Tsongas Visits Lawrence-based Medical Device Maker NxStage Medical, Inc.
6. Emil Paganini, MD, Joins NxStage(R) as Critical Care Medical Advisor
7. NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
8. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
9. NxStage(R) Medical to Report Fourth Quarter & Full Year 2007 Financial Results on Tuesday, February 12th
10. NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
11. NxStage Medical Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... ... However, choosing the right method is paramount to success. Selecting an inappropriate measurement ... situations where multiple persons use the same equipment. Rare or expensive substances are ...
(Date:1/23/2017)... ... January 23, 2017 , ... Gynecology ... care and gynecological services for women of all ages. The staff ... wide variety of reproductive services from routine health screenings to diagnosing and treating ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of Christ”: ... Infallible Characteristics of Christ” is the creation of published author, Rev. Dr. Robert W. ... for thirteen years, a preacher for over nineteen, a pastor for over fifteen years. ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals ... of a simple test will take days to arrive to the end customer, having ... direct access to their lab tests, bypassing the cost and delay of traditional means. ...
(Date:1/21/2017)... , ... January 21, 2017 , ... Phytocéane ... Ocean, isolated from the rest of the world with ZANZIBAR SHOWER GEL. Inspired by ... used key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017 ARMO BioSciences, ... clinical data on the Company,s lead investigational immuno-oncology drug ... co-sponsored by the American Society of Clinical Oncology (ASCO), ... Francisco, CA. "AM0010 induces ... CD8 + T cells in the blood and ...
(Date:1/20/2017)... 2017 Research and Markets has announced ... ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic ... Forecasts, 2013 - 2024" report to their offering. ... The global clinical laboratory ... Introduction of innovative solutions on the grounds of maximum ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... to their offering. ... This research service on the global pharmaceutical stability testing market ... of the key participants in the market. The ... 2020. The market is expected to grow at a CAGR of ...
Breaking Medicine Technology: